Home
 /
Papers
 /
Genetics
 /
Genome-scale perturb-seq in primary human CD4+ T cells maps context-specific regulators of T cell programs and human immune traits
Preprint
Open access
Top 1% · Validated by QED

Genome-scale perturb-seq in primary human CD4+ T cells maps context-specific regulators of T cell programs and human…

Ronghui Zhu, Emma Dann, Jun Yan +7 more
December 2025
 ·
bioRxiv
 ·
DOI 
10.64898/2025.12.23.696273
99
%
QED Score
QED Impressions

Genome-scale Perturb-seq in primary human T cells—previously impossible—reveals that regulatory networks rewire dramatically across activation states and establishes a foundational resource connecting immune gene function directly to autoimmune disease risk and aging phenotypes.

Run full QED analysis
Read paper
Save

QED claims analysis

Summary

Genome-scale CRISPR perturbation-sequencing in primary human CD4+ T cells across multiple stimulation conditions reveals context-specific gene regulatory networks that systematically identify regulators of immune cytokine production, predict causal factors driving natural T cell states observed in human populations, and mechanistically interpret genetic associations with complex immune traits and autoimmune diseases.

See full analysis
Main Claim 1 –

Genome-scale perturb-seq maps regulatory relationships in primary CD4+ T cells

Supporting evidence

  • Perturb-seq effects replicate across donors and independent validation assays
  • Donor replication and cell coverage optimize perturb-seq trans-effect detection
Main Claim 2 –

Perturb-seq maps cytokine-production regulatory networks in CD4+ T cells

Supporting evidence

  • Arrayed knockdowns validate perturb-seq IL10 and IL21 regulators
Main Claim 3 –

Functional clustering reveals context-specific CD4+ T cell regulatory programs

Main Claim 4 –

Perturbation signatures predict regulators of natural human T cell states

Supporting evidence

  • Perturbation signatures predict regulators of age-associated CD4+ T cell programs

Abstract

Gene regulatory networks encode the fundamental logic of cellular functions, but systematic network mapping remains challenging, especially in cell states relevant to human biology and disease. Here, we perturbed all expressed genes across 22 million primary human CD4+ T cells from four donors and developed a probe-based perturb-seq platform to measure the transcriptome effects in cells at rest and after stimulation. These data allow us to map genes that regulate known and novel pathways, including novel regulators of cytokine production. Importantly, active regulators and the gene programs they control change dramatically across stimulation conditions. Perturbation signatures enabled us to model T cell states observed in population-scale transcriptomic atlases, nominating regulators of Th1 and Th2 polarization and of age-related T cell phenotypes. Finally, we leveraged perturb-seq to implicate context-specific gene regulatory pathways in autoimmune disease risk. Our data provide a foundational resource to decode human immune function and genetic variation and for new approaches to study gene regulatory networks.

Related papers

How the QED Score works

QED Score is an AI-based quality metric for life science research. It rates each paper on two dimensions: originality (is the finding new and important?) and validity (does the evidence support the claims?). Author names and affiliations are removed before scoring. Each manuscript is broken down into its claims and the experiments behind them, and specialized AI agents then examine those claims for statistical rigor, consistency across figures, and contradictions with the existing literature. A verification layer re-checks every issue they flag. Scores are percentile ranks against all papers in the corpus. In a blinded study of papers where QED Score and journal rank disagreed, domain experts sided with QED Score in 75% of cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?